ArticleAmerican journal of nuclear medicine and molecular imaging2016
(68)Ga-DOTATOC PET and gene expression profile in patients with neuroendocrine carcinomas: strong correlation between PET tracer uptake and gene expression of somatostatin receptor subtype 2.
Article in American journal of nuclear medicine and molecular imaging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Prospective Phase II Trial of Prognostication byJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Trial
- Gastroenteropancreatic Neuroendocrine Neoplasms: Clinical and Translational Perspectives.JMA journal · 2026Review
- Correlation of [EJNMMI research · 2026Article
- [European journal of nuclear medicine and molecular imaging · 2026Article
- Paving the Way for CCK2R-Targeted Peptide Receptor Radionuclide Therapy with [Pharmaceutics · 2026Article
- Prediction ofCancers · 2023Article
- Diagnostic Management of Gastroenteropancreatic Neuroendocrine Neoplasms: Technique Optimization and Tips and Tricks for Radiologists.Tomography (Ann Arbor, Mich.) · 2023Review
- PET-CT in Clinical Adult Oncology-VI. Primary Cutaneous Cancer, Sarcomas and Neuroendocrine Tumors.Cancers · 2022Review
- Correlation of Somatostatin Receptor 1-5 Expression, [Cancers · 2021Article
- Somatostatin and Its Receptor System in Colorectal Cancer.Biomedicines · 2021Review
- Prospective study of dynamic whole-body 68Ga-DOTATOC-PET/CT acquisition in patients with well-differentiated neuroendocrine tumors.Scientific reports · 2021Article
- Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors.Journal of clinical medicine · 2020Review
- Article
- Review
- [Neuroendocrine tumors of the stomach, duodenum and pancreas : Value of (hybrid) radiological diagnostics].Der Radiologe · 2019Review
- Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin.Scientific reports · 2019Article
- Radionuclide generators: the prospect of availing PET radiotracers to meet current clinical needs and future research demands.American journal of nuclear medicine and molecular imaging · 2019Review
- Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.Current opinion in endocrinology, diabetes, and obesity · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Somatostatin receptor expression on both protein and gene expression level was compared with in vivo (68)Ga-DOTATOC PET/CT in patients with neuroendocrine carcinomas (NEC). Twenty-one patients with verified NEC who underwent a (68)Ga-DOTATOC PET/CT between November 2012 and May 2014, were retrospectively included. By real-time polymerase chain reaction, we quantitatively determined the gene expression of several genes and compared with (68)Ga-DOTATOC PET uptake. By immunohistochemistry we qualitatively studied the expression of assorted proteins in NEC. The median age at diagnosis was 68 years (range 41-84) years. All patients had WHO performance status 0-1. Median Ki67 index was 50% (range 20-100%). Gene expression of somatostatin receptor subtype (SSTR) 2 and Ki67 were both positively correlated to the (68)Ga-DOTATOC uptake (r=0.89; p<0.0001 and r=0.5; p=0.021, respectively). Furthermore, SSTR2 and SSTR5 gene expression were strongly and positively correlated (r=0.57; p=0.006). This study as the first verifies a positive and close correlation of (68)Ga-DOTATOC uptake and gene expression of SSTR2 in NEC. SSTR2 gene expression has a stronger correlation to (68)Ga-DOTATOC uptake than SSTR5. In addition, the results indicate that the gene expression levels of SSTR2 and SSTR5 at large follow one another.
Indexed as
Identifiers
27069766PMC4749505W2419187100What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.